Skip to main content
. Author manuscript; available in PMC: 2015 Oct 3.
Published in final edited form as: Cancer Gene Ther. 2015 Apr 3;22(4):215–221. doi: 10.1038/cgt.2015.14

Figure 4.

Figure 4

Representative coronal (A,B) and transaxial (C,D) views of maximum-intensity projections of PET images with co-registered CT of mice bearing MCF-7 tumors at 4 h after injection of 64Cu-CB-TE2A-Y3-TATE. The axillary tumors were injected directly with AdSSTR2-yCD (A,C) or saline (B,D) two days prior to administration of 64Cu-CB-TE2A-Y3-TATE. The images show uptake of 64Cu-CB-TE2A-Y3-TATE in the AdSSTR2-yCD injected tumors, but not the control tumors. The white arrows indicate location of the tumors, the red arrows indicated radioactive excretion through the bladder, and the yellow arrows indicate the location of the kidney. Clearance of 64Cu-CB-TE2A-Y3-TATE through the kidneys is observed in mice where the kidneys are in the field of view (yellow arrows). Panel E shows the SUV analysis for the tumors injected with AdSSTR2-yCD or saline (control). In addition, SUV analysis was performed on a group of mice that received saline followed by co-injection of 64Cu-CB-TE2A-Y3-TATE and 200 µg of Y3-TATE as a blocking agent (control + block).